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Abstract
AIM: To investigate the cytoprotective effects in hepatic 
ischemia-reperfusion injury, we developed a new 
formulation of hyaluronic acid (HA) and sphingosine 
1-phophate.
METHODS: We divided Sprague-Dawley rats into 4 
groups: control, HA, sphingosine 1-phosphate (S1P), 
and HA-S1P. After the administration of each agent, 
we subjected the rat livers to total ischemia followed 
by reperfusion. After reperfusion, we performed the 
following investigations: alanine aminotransferase (ALT), 
histological findings, TdT-mediated dUTP-biotin nick end 
labeling (TUNEL) staining, and transmission electron 
microscopy (TEM). We also investigated the expression 
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Basic Study
New drug delivery system for liver sinusoidal endothelial 
cells for ischemia-reperfusion injury
proliferation, differentiation, migration and survival 
through interaction with different G protein-coupled 
S1P receptors[6,7]. S1P exhibits anti-apoptotic effects on 
human LSECs[8] and protects rat LSECs from ethanol-
induced apoptosis[9]. In addition S1P also reduces 
hepatic I/R-induced acute kidney injury through the 
attenuation of endothelial injury in mice[10]. However, 
accumulating S1P (as a single-agent) on the LSECs 
is difficult, as S1P receptors are widely expressed in 
various different tissues, such as brain, heart, lung, 
spleen, kidney, intestine, testis, and liver[11-13]. 
In this study, we developed a new drug delivery 
system (DDS) for targeting the LSEC by combining 
S1P with HA, to make the formula HA-S1P. Circulating 
HA in the blood is taken up through receptor-
mediated endocytosis into the LSECs[14] because 
the HA receptors, namely Stabilin-2 (STAB2), are 
highly  and  speciﬁcally  expressed  on  LSECs.  STAB2  is  
a type Ⅰ transmembrane scavenger receptor that is 
highly expressed in LSECs and is the major clearance 
receptor for circulating HA[15-19]. We hypothesized 
that HA-S1P would accumulate in LSECs of liver via 
the STAB2 receptors. The aim of this study was to 
investigate whether the newly developed HA-S1P 
protects livers in the case of hepatic I/R injury. 
MATERIALS AND METHODS
Materials
S1P was purchased from Sigma Chemical Company (St. 
Louis, MO, United States) and HA [average molecular 
weight (MW) 8 kDa] was purchased from Food 
Chemifa (Tokyo, Japan). 
Synthesis of HA-S1P
A mixture was made of 95.85 L 1-ethyl-3- (3-dime-
thylaminopropyl) carbodiimide hydrochloride (EDC) 
(0.1 g/mL), 57.535 L N-hydroxysuccinimide (NHS) 
(0.1 g/mL), HA (2 mg/mL, average MW 8 kDa), and 
water/DMF/CHCl3 (5/4/1). The mixture was stirred 
well at 55 ℃ with the addition of 67.378 L S1P (25 
mg/mL), and the reaction was allowed to proceed for 
24 h. Dialysis was performed to remove the S1P, EDC, 
and NHS. Integrations of nuclear magnetic resonance 
(NMR) were used to confirm the amount of S1P 
introduced [comparison of peaks appeared at 1.2 ppm 
(methylene group of S1P) and 2.0 ppm (acetyl group 
of hyaluronic acid)]. Approximately 13.5%-40% of S1P 
bound to the carboxylic acid of HA.
Animal model
Male Sprague-Dawley rats, weighing 200 to 250 g, 
were obtained from CLEA Japan (CLEA Corporation, 
Tokyo, Japan). Animal experiments were performed 
in a humane manner after receiving approval from 
the Institutional University Experiment Committee 
of the University of Tsukuba, and in accordance with 
the university’s Regulations for Animal Experiments 
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of proteins associated with apoptosis, hepatoprotection, 
and S1P accumulation. 
RESULTS: S1P accumulated in the HA-S1P group 
livers more than S1P group livers. Serum ALT levels, 
TUNEL-positive hepatocytes, and expression of cleaved 
caspase-3 expression, were significantly decreased 
in the HA-S1P group. TEM revealed that the liver 
sinusoidal endothelial cell (LSEC) lining was preserved 
in the HA-S1P group. Moreover, the HA-S1P group 
showed a greater increase in the HO-1 protein levels 
compared to the S1P group.
CONCLUSION: Our results suggest that HA-S1P 
exhibits cytoprotective effects in the liver through the 
inhibition of LSEC apoptosis. HA-S1P is an effective 
agent for hepatic ischemia/reperfusion injury.
Key words: Hyaluronic acid; Sphingosine 1-phosphate; 
Liver sinusoidal endothelial cell; Drug delivery system; 
Heme oxygenase-1; Stabilin-2
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: We have developed a new formulation by 
directly combining hyaluronic acid and sphingosine 
1-phosphate (HA-S1P), which targets liver sinusoidal 
endothelial cell (LSEC) by binding specifically to HA and 
HA receptors. This study demonstrated that HA-S1P 
protects the liver from hepatic ischemia/reperfusion (I/
R) injury in rats. The strong protective effect of HA-S1P 
may be mediated by the anti-apoptotic effect of S1P on 
LSECs. These data indicate that HA-S1P is an effective 
agent for preventing hepatic I/R injury.
Sano N, Tamura T, Toriyabe N, Nowatari T, Nakayama K, Tanoi 
T, Murata S, Sakurai Y, Hyodo M, Fukunaga K, Harashima H, 
Ohkohchi N. New drug delivery system for liver sinusoidal 
endothelial cells for ischemia-reperfusion injury. World J 
Gastroenterol 2015; 21(45): 12778-12786  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i45/12778.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i45.12778
INTRODUCTION
Hepatic ischemia/reperfusion (I/R) injury is a major 
problem in liver transplantation and liver resection[1]. A 
critical event during hepatic I/R injury is the death of 
liver sinusoidal endothelial cells (LSECs), which occurs 
within a few minutes of reperfusion and precedes 
hepatocyte death by several hours[2]. The apoptosis of 
LSECs is a pivotal mechanism of hepatic I/R[3]. Thus, 
apoptosis plays an important role in hepatic I/R injury 
and LSEC death[4] and therefore LSECs are the primary 
treatment target for hepatic I/R injury[5]. 
Sphingosine-1-phosphate (S1P) is a bioactive lipid 
that regulates diverse cellular functions, including 
and Fundamental Guidelines for Proper Conduct of 
Animal Experiment and Related Activities in Academic 
Research Institutions, under the jurisdiction of the 
Japanese Ministry of Education, Culture, Sports, 
Science, and Technology.
Experimental groups
Total warm hepatic ischemia was induced in the rats 
for 20 min by clamping the portal triad. The rats were 
divided into 4 groups as follows: (1) methanol injection 
group (control group; n = 15); (2) HA injection group 
(HA group; n = 10); (3) single-agent S1P injection 
group (S1P group; n = 11); and (4) HA-S1P injection 
group (HA-S1P group; n = 10) (Figure 1). Methanol, 
S1P, HA, or HA-S1P were injected intravenously via the 
tail vein of the rats. 
Surgical procedure
The rats were anesthetized with intraperitoneal 
injections of sodium pentobarbital (50 mg/kg) and 
maintained by machine-regulated isoflurane. The 
rats were placed in a supine position on a heated 
pad to maintain a rectal temperature of 37 ℃. After 
transverse laparotomy, the ligaments around the 
liver were dissected in order to clamp the portal triad. 
Concurrently, the hepatoduodenal ligament was 
taped in preparation for the subsequent clamping. 
Hepatic ischemia was induced via clamping of the 
portal triad, i.e., the hepatic artery, portal vein, and 
bile duct, by means of a microclip (B. Braun Aesculap 
Japan Co., Ltd, Tokyo, Japan) for 20 min. Surgical 
procedures were performed under sterile conditions. 
Blood samples were taken for the analysis of enzyme 
activities in serum before ischemia and at 30, 60, 
and 120 min after reperfusion. At the end of the 
experiments, liver tissue was obtained for histological 
examination. Finally, the experimental animals were 
euthanized by total blood collection via the abdominal 
aorta. During the period from drug administration 
until  sacriﬁced,  respiratory  and  circulatory  dynamics  of  
rats was stable. Moreover, all of rats did not die in this 
experiment.
Serum alanine transaminase levels
To assess damage to the hepatic parenchyma, serum 
alanine transaminase (ALT) levels were measured 
using  a  Dry-­Chem  7000  V  autoanalyzer  (Fujiﬁlm  Co,  
Tokyo, Japan). Blood samples were taken from the tail 
vein before the induction of ischemia and up to 120 
min after reperfusion.
Histological analysis
After 120 min of reperfusion, liver tissues were obtained 
from each group, fixed with 10% formaldehyde, and 
embedded in paraffin. Thin sections (4 m) were 
prepared and stained with hematoxylin-eosin (HE). 
Tissue damage was evaluated in randomly selected 
high-­power  ﬁelds  (×  200).
Liver apoptosis
To detect apoptotic cells in liver tissue, a terminal 
deoxynucleotidyl transferase-mediated dUTP nick end 
labeling (TUNEL) assay (In situ Apoptosis Detection Kit; 
Takara Bio Inc., Otsu, Japan) was performed after 120 
min of reperfusion. The ratio of TUNEL-positive/total 
cells  in  the  microscope  ﬁeld  was  calculated  at  ×  400.
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HA group (n  = 10)
S1P group (n  = 11)
HA-S1P group (n  = 10)
Control group (n  = 15)
-30 min -20 min 0 min 30 min 60 min 120 min
Methanol 20-min ischemia of liver
Blood sample Sacrifice
-30 min -20 min 0 min 30 min 60 min 120 min
HA + Methanol 20-min ischemia of liver
Blood sample Sacrifice
-30 min -20 min 0 min 30 min 60 min 120 min
S1P (100 g/kg) + Methanol 20-min ischemia of liver
Blood sample Sacrifice
-30 min -20 min 0 min 30 min 60 min 120 min
HA-S1P (S1P 100 g/kg) + Methanol 20-min ischemia of liver
Blood sample Sacrifice
Figure 1  Experimental groups. Total hepatic ischemia was established for 20 min by clamping the portal triad in the rat subjects. The rats were divided into 4 
groups: (1) control group; (2) HA group; (3) S1P group; and (4) HA-S1P group. Each drug was injected via the tail vein 10 min before ischemia. HA: Hyaluronic acid; 
S1P: Sphingosine 1-phosphate.
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U-test with Bonferroni correction. P values of < 0.05 
were  considered  statistically  signiﬁcant.
RESULTS
Serum ALT levels
In the control, HA, and S1P groups, serum ALT (which 
reflects the degree of hepatic parenchymal injury) 
immediately increased after reperfusion. However, in 
the HA-S1P group serum ALT levels were unchanged 
up to 120 min (Figure 2). 
Histological  ﬁndings
The light microscopy findings from the liver tissue, 
stained with HE, are shown in Figure 3A. In the control, 
HA and S1P groups, vacuolation of the hepatocytes 
and sinusoidal narrowing were observed after 120 
min  of  reperfusion.  These  ﬁndings  were  more  severely  
localized near the portal vein. On the other hand, no 
histological alteration was observed in the HA-S1P 
group. 
Liver apoptosis and western blot analysis
In the control, HA, and S1P groups, TUNEL-positive 
cells were observed after 120 min of reperfusion near 
the portal vein. However, TUNEL-positive cells were not 
observed in the HA-S1P group (Figure 3B). The ratio of 
TUNEL-positive to total hepatocytes was significantly 
lower in the HA-S1P group (Figure 3C). Western blot 
analysis of the liver tissue is presented in Figure 4. The 
expression of cleaved caspase-3 in the control, HA, and 
S1P groups was extremely higher than that in the HA-
S1P group (Figure 4A). The expression of the HO-1 (a 
cytoprotective enzyme against hepatic I/R injury) in the 
HA-S1P group was higher than that in the control, HA, 
and S1P groups (Figure 4B). 
Drug delivery system
In the control and HA groups, S1P did not accumulate 
in the liver. In the HA-S1P group, S1P accumulated 
in the liver to a greater degree than it did in the S1P 
group (Figure 4C). 
Transmission electron microscopy
Deterioration of the sinusoidal endothelial lining was 
observed and severe destruction of the perisinusoidal 
space structures were observed in the control, HA, and 
S1P groups (Figure 5). In the HA group vacuolation 
induced by hypoxia was observed. However, the 
structure of the endothelial lining in the HA-S1P group 
was well preserved. Moreover, it was no obvious 
mitochondrial disorders in the HA-S1P group.
DISCUSSION
LSECs play important functional roles in hepatic I/R 
injury, being particularly vulnerable to it[20,21]. S1P has 
an anti-apoptotic effect on LSECs[8,9], but S1P receptors 
Protein extraction and Western blot analysis
Liver tissues were kept at -80 ℃ and were homogenized 
in a buffer consisting of 150 mmol/L NaCl, 50 mmol/L 
TrisCl, 1% NP-40, and proteinase inhibitors. The 
samples were centrifuged, and the supernatants 
collected for analysis. The samples were separated 
on 10% and 15% SDS-PAGE gels and transferred 
to nitrocellulose membranes (Millipore, Bedford, MA, 
United States). Anti-cleaved caspase-3 (9661), anti-
heme oxygenase 1 (HO-1) (5141) (Cell Signaling 
Technology, Beverly, MA, United States) and anti-
S1P antibodies (140592) (Abcam Ltd., Cambridge, 
United Kingdom) were used as primary antibodies. 
A secondary goat anti-rabbit antibody conjugated to 
horseradish peroxidase was purchased from Zymed 
Laboratories (San Francisco, CA, United States).
Transmission electron microscopy
To assess the LSECs after hepatic I/R, we investigated 
the samples using transmission electron microscopy 
(TEM). After 120 min of reperfusion, the livers were 
resected. Tissue samples from the left hepatic lobe 
were cut into 1 mm3 cubes and stored in 2.5% 
glutaraldehyde. The specimens were postfixed with 
osmium tetroxide, dehydrated in graded alcohol series 
and embedded in Epon mixture. Ultrathin sections 
were prepared using an Ultracut S microtome (Leica 
Aktiengesellschaft, Vienna, Austria) and placed on 
copper grids. Sections were treated using uranyl acetate 
and lead citrate to enhance contrast. Specimens were 
examined using a Hitachi H-7000 transmission electron 
microscope (Hitachi Co., Tokyo, Japan).
Statistical analysis
All data are expressed as the mean ± SD. The Mann-
Whitney U-test and Kruskal-Wallis H-test were used 
for statistical analysis, followed by the Mann-Whitney 
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Figure 2  Serum alanine aminotransferase levels. Serum ALT levels before 
ischemia and after reperfusion. Kruskal Wallis H-test. aP < 0.05 vs HA group; 
cP < 0.05 vs control and the HA and S1P groups; eP < 0.05 vs control and S1P 
groups. ALT: Alanine aminotransferase; HA: Hyaluronic acid; S1P: Sphingosine 
1-phosphate; I/R: Ischemia/reperfusion.
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are widely expressed in many organs[11-13]. Thus, it is 
difﬁcult  to  deliver  agents  speciﬁcally  to  LSECs  through  
a single-agent administration of S1P. However, HA 
receptors of STAB2 are specifically expressed on 
LSECs[15-19]. We have developed a new formulation of 
HA-S1P that targets LSECs by binding specifically to 
HA and HA receptors. This study demonstrates that 
HA-S1P protects the liver from hepatic I/R injury in 
rats and that the strong protective effect of HA-S1P 
may be mediated by the antiapoptotic effect of S1P 
on LSECs. Therefore, the results of this study strongly 
suggest that HA-S1P could be a useful agent for 
suppressing hepatic I/R injury.
In hepatic I/R injury, LSECs are injured and become 
apoptotic soon after reperfusion and this phenomenon 
occurs much earlier than it does in hepatocytes[22]. 
In addition, LSECs have important functional roles 
throughout hepatic injury in acute hepatitis[23] and 
hepatectomy[24]. In general, LSECs are known to 
be a septum between blood and hepatocytes and 
are involved in the stabilization of hepatocytes. In 
previously research we determined that LSEC injury 
results  in  microcirculatory  blood  ﬂow  disturbances[25]. In 
I/R injury, hepatocytes become seriously impaired after 
disorder of the LSECs, which subsequently induces liver 
dysfunction[26]. As such, LSECs are primary therapeutic 
targets of hepatic I/R injury[26]. In the present study 
we performed total hepatic I/R injury in rats and we 
found that serum alanine aminotransferase levels were 
also significantly relieved by HA-S1P administration. 
TEM findings supported our hypothesis that HA-S1P 
has a positive effect on LSEC injury. After HA-S1P 
administration there were no observations of apoptotic 
cells in the liver tissue thus preventing hepatic I/R 
injury. These results indicate that HA-S1P administration 
inhibits the deterioration of the LSEC lining structure 
and that this phenomenon leads to the suppression of 
hepatic injury.
S1P is a lipid mediator contained in platelets and 
is reported to regulate a broad variety of cellular 
processes, such as cell proliferation, apoptosis, calcium 
homeostasis, vascular maturation, or angiogenesis[27,28]. 
S1P is excreted in large amounts from activated 
platelets[29]. Zheng et al[9] reported that S1P protects 
LSECs from ethanol-induced injury through inhibition 
of apoptosis and we have previously reported that 
S1P prevents the apoptosis of LSECs by inhibiting 
12783 December 7, 2015|Volume 21|Issue 45|WJG|www.wjgnet.com
Figure 3  Histological ﬁndings. A: HE staining In the control (a), HA (b), and S1P group (c) histologic examination revealed vacuolation of the hepatocytes and loss 
of  palisade  arrangement  after  120  min  of  reperfusion.  These  ﬁndings  were  not  observed  in  the  HA-­S1P  group  (d).  (hematoxylin-­eosin  stain,  magniﬁcation  ×  200);;  B:  
TUNEL (TdT-mediated dUTP-biotin nick end labeling) assay of the liver tissue and (C) the ratio of TUNEL-positive/total hepatocytes In the control (a), HA (b), and S1P 
groups  (c),  TUNEL-­positive  cells  were  observed  in  zone  1  after  120  min  of  reperfusion.  These  ﬁndings  were  not  observed  in  the  HA-­S1P  group  (d).  
bP < 0.01 vs the 
control, HA, and S1P groups. HA: Hyaluronic acid; S1P: Sphingosine 1-phosphate.
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Figure 4  Western blot analysis of cleaved caspase-­3 (A), heme oxygenase-­1 
(B) and sphingosine 1-­phosphate (C) in liver tissues. The expression of 
cleaved caspase-3 in the control, HA, and S1P groups, was higher than that in 
the HA-S1P group. The expression of HO-1 in the HA-S1P group was higher 
than that in the control, HA, and S1P group. The expression of S1P in the HA-
S1P group was higher than in the control, HA, or S1P groups. HO-1: Heme 
oxygenase 1; HA: Hyaluronic acid; S1P: Sphingosine 1-phosphate.
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the cleavage of caspase-3[8]. From these reports, we 
hypothesized that S1P is the most effective agent 
for inhibiting hepatic I/R injury, because apoptosis of 
LSEC is the primary mechanism underlying hepatic 
I/R injury[30,31]. S1P acts directly either on intracellular 
targets or activates G protein-coupled receptors[32]. Five 
S1P  receptors  have  been  identiﬁed,  namely  S1PR1-­5[33]. 
S1PR1-3 are widely expressed in various tissues 
(including liver), whereas the expression of S1PR4 and 
S1PR5  are  conﬁned  to  lymphoid/hematopoietic  tissue  
and to the central nervous system, respectively[33]. 
Recent investigations revealed that LSECs possess 
unique HA receptors of STAB2 that recognize and 
internalize HA[34]. We tried to utilize this feature of 
LSECs in the development of a novel DDS to achieve 
the accumulation of S1P[35]. Exogenous HA has been 
reported to rapidly integrate into the liver after in vivo 
administration[15,17]. HA has been widely used as a 
targeted delivery material for LSECs[36]. However, up 
to  now,  there  has  been  no  speciﬁc  research  focused  on  
LSECs that has lead to the treatment of liver disease. 
To this end we developed HA-S1P formulation that is 
prepared by direct combination of HA and S1P. In the 
present study, we revealed that HA-S1P selectively 
accumulates in the liver to a greater extent than dose 
a single-agent administration of S1P. 
HO-1 is widely expressed among the different liver 
cell populations, including LSECs, hepatocytes, Kupffer 
cells and hepatic stellate cells[37]. The cytoprotective 
effects of HO-1 have been shown to ameliorate hepatic 
I/R injury in various experimental models[38]. We have 
previously demonstrated that HO-1 overexpression 
exerts cytoprotective effects and improves hepatic I/R 
injury[39]. HO-1, also known as heat shock protein 32, 
is an inducible enzyme that converts heme into carbon 
monoxide (CO), billiverdin and free iron[40]. Moreover, 
induction of CO in the hepatic sinusoids before hepatic 
I/R may have prominent effects[39]. In the present 
study, we found that HA-S1P resulted in greater 
expression of HO-1 than single-agent administration 
of S1P. Consequently, these data suggest that by 
inducing HO-1 to maintain normal cellular function HA-
S1P protects LSECs from hepatic I/R injury. 
In  conclusion,  we  have  succeeded  in  speciﬁc  delivery  
of S1P to LSECs for the first time by using HA as a 
carrier. Furthermore, HA-S1P exhibits a cytoprotective 
effect on the liver through the inhibition of LSEC 
apoptosis. HA-S1P attenuates hepatic I/R injury 
by protecting LSECs, which represent the primary 
therapeutic targets for treating hepatic I/R injury. 
Thus, HA-S1P is a promising new agent for hepatic I/R 
injury. Further investigations are needed to support 
our results and elucidate the molecular mechanisms.
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Figure 5  Transmission electron microscopic ﬁndings after 120 min of hepatic ischemia/reperfusion.   In   the  control   (A),  HA  (B),  and  S1P  groups  (C),   the  
sinusoidal endothelial linings were destroyed and detached into the sinusoidal space. In contrast, in the HA-S1P group (D), the sinusoidal endothelial cells were well 
preserved. HA: Hyaluronic acid; S1P: Sphingosine 1-phosphate; LSEC: Liver sinusoidal endothelial cell.
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Background
The apoptosis of liver sinusoidal endothelial cells (LSECs) is a pivotal 
mechanism of hepatic ischemia/reperfusion (I/R). Sphingosine 1-phosphate 
(S1P) exhibits antiapoptotic effects on human LSECs. However, accumulating 
S1P  (as  a  single-­agent)  on  the  LSECs  is  difﬁcult,  as  S1P  receptors  are  widely  
expressed in various different tissues. The authors developed a new drug 
delivery system for targeting the LSEC by combining S1P with HA, to make the 
formula hyaluronic acid-S1P (HA-S1P). The aim of this study was to investigate 
whether the newly developed HA-S1P protects livers in the case of hepatic I/R 
injury. 
Research frontiers
LSECs  play  important  functional  roles  in  hepatic  I/R  injury.  It  is  difﬁcult  to  deliver  
protective  agents  speciﬁcally   to  LSECs  through  a  single-­agent  administration.  
However,  HA  receptors  of  STAB2  are  speciﬁcally  expressed  on  LSECs.  The  
authors have developed a new formulation of HA-S1P that targets LSECs by 
binding  speciﬁcally  to  HA  and  HA  receptors  to  protect  the  liver  from  hepatic  I/R  
injury.
Innovations and breakthroughs
This   is   the  ﬁrst  study  to  succeed   in  speciﬁc  delivery  of  S1P  to  LSECs  for   the  
ﬁrst  time  by  using  HA  as  a  carrier.  There  has  been  no  speciﬁc  research  focused  
on LSECs that has lead to the treatment of liver disease. HA-S1P attenuates 
hepatic I/R injury by protecting LSECs.
Applications
Hepatic I/R injury is a major problem in liver transplantation and liver resection. 
The authors suggest that HA-S1P is a promising new agent for hepatic I/R 
injury.
Terminology
S1P is a bioactive lipid that regulates diverse cellular functions, including 
proliferation, differentiation, migration and survival through interaction 
with different G protein-coupled S1P receptors. The HA receptors, namely 
STAB2,   are   highly   and   specifically   expressed   on   LSECs.   STAB2   is   a  
type Ⅰ transmembrane scavenger receptor that is highly expressed in LSECs 
and is the major clearance receptor for circulating HA.
Peer-review
The authors have developed a new formulation of HA-S1P that targets LSECs 
by  binding  speciﬁcally   to  HA  and  HA  receptors.  This  study  demonstrates  that  
HA-S1P protects the liver from hepatic I/R injury in rats and that the strong 
protective effect of HA-S1P may be mediated by the antiapoptotic effect of S1P 
on LSECs. Therefore, the results of this study strongly suggest that HA-S1P 
could be a useful agent for suppressing hepatic I/R injury.
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